IL35 Level in Vitiligo

Assessment of Tissue Levels of IL-35 in Active and Stable Vitiligo

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05980390

Enrollment

Registered

2023-08-08

Start date

2023-08-10

Completion date

2023-10-30

Last updated

2023-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IL35, Vitiligo

Brief summary

The aim of this observational study is to evaluate the level of the IL-35 protein in tissue biopsy from patients with active & stable vitiligo.

Interventions

DIAGNOSTIC_TESTIL 35 in tissue biopsy

Elisa testing

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Inclusion criteria

* Patients with active and stable vitiligo

Exclusion criteria

* Pregnant and lactating women. * Patients with associated autoimmune or other dermatological diseases e.g., Alopecia areata and lupus erythematous. * Patients already on both topical and systemic treatment at the time of recruitment. * Patients on Immunosuppressive drugs. * Other hypopigmented diseases such as pityriasis alba, tinea versicolor, lichen sclerosis, post inflammatory hypopigmentation and leprosy as excluded by lack of accentuation by wood's light examination.

Design outcomes

Primary

Measure	Time frame
level of IL35 in tissue biopsy	3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026